The Commercialization
Readiness Gap in MedTech

Medtech success is decided less by a single breakthrough and more by whether a company's commercialization logic survives a series of external gates — funding diligence, regulatory pathways, hospital procurement, reimbursement, and operational adoption. The commercialization readiness gap is the space between what teams believe is true about their go-to-market and what must be true for institutions to commit money, workflow, and reputational risk.

Recent benchmarks show how selectively this system advances companies. In venture markets, only 15.4% of startups that raised a seed round in Q1 2022 reached Series A within two years (down from 30.6% for Q1 2018)^[1], indicating a materially tougher bar for credible scale narratives in the current environment. In medtech-specific competitive funnels, one of the largest accelerators reports a 4% acceptance rate for its 2025 cohort^[2], illustrating how sharply diligence filters apply even before traditional financing. On the buyer side, healthcare AI benchmarking found that only 30% of completed proofs of concept reached production — a healthcare AI-specific dataset used here as a directional proxy for broader institutional adoption dynamics — reinforcing that pilots are common but scaled adoption is not.^[3]

Importantly, clearing a gate is not the same as commercialization. In a peer-reviewed analysis of U.S. claims usage of medical AI procedures, the authors report over 500 FDA-approved medical AI devices, yet adoption is still nascent, concentrated in a handful of high-utilization procedures; only coronary artery disease assessment and diabetic retinopathy diagnosis exceeded 10,000 CPT claims in the dataset.^[4] Separately, a 2025 cross-sectional study of 903 FDA-approved AI-enabled medical devices found that clinical performance studies were reported for approximately half the devices analyzed, while one-quarter explicitly stated that no such studies had been conducted at approval — an evidence-clarity gap that can directly weaken procurement and partnership confidence.^[5]

This white paper synthesizes what these data imply: many failures are not technology failures; they are commercialization readiness failures — unclear buyer and budget logic, misaligned evidence relative to decision thresholds, reimbursement friction, workflow and integration barriers, and decision-making processes that are committee-based and risk-managed.

The strongest available public statistics do not usually label themselves commercialization failure rates, because commercialization is not one event and medtech categories vary widely. What we do have are validated proxies: how often companies clear funding progression gates, how often pilots become production deployments, and how often products are used at scale after authorization.

Evidence from medtech benchmarking suggests that organizations investing earlier in market understanding tend to outperform on commercialization outcomes. Deloitte and AdvaMed report that top-performing companies generated three times more revenue from recently launched products and invested more heavily in early-stage market understanding activities.^[11]

This relationship should be interpreted directionally rather than causally. The data does not prove that early validation causes better outcomes, but it is consistent with a broader pattern: companies that align buyer, evidence, and economic logic earlier are less likely to encounter downstream commercialization friction.

In practice, early commercial validation focuses on resolving a small number of critical uncertainties before they become expensive:

• Who actually signs and pays
• What evidence threshold is required for approval
• Where budget originates
• What operational burden adoption creates
• What must be true for repeatable revenue

Addressing these questions early does not guarantee success. It reduces avoidable failure.